Contrasting Aevi Genomic Medicine (GNMX) & Affymax (AFFY)
Aevi Genomic Medicine (NASDAQ: GNMX) and Affymax (OTCMKTS:AFFY) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
This is a summary of recent recommendations and price targets for Aevi Genomic Medicine and Affymax, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aevi Genomic Medicine||0||1||1||0||2.50|
Aevi Genomic Medicine presently has a consensus price target of $4.25, suggesting a potential upside of 145.66%. Given Aevi Genomic Medicine’s higher probable upside, equities analysts clearly believe Aevi Genomic Medicine is more favorable than Affymax.
Risk and Volatility
Aevi Genomic Medicine has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Affymax has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.
This table compares Aevi Genomic Medicine and Affymax’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aevi Genomic Medicine||N/A||-125.94%||-106.93%|
Valuation & Earnings
This table compares Aevi Genomic Medicine and Affymax’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Aevi Genomic Medicine||N/A||N/A||-$37.80 million||($1.02)||-1.70|
Aevi Genomic Medicine has higher revenue, but lower earnings than Affymax.
Institutional and Insider Ownership
20.8% of Aevi Genomic Medicine shares are held by institutional investors. 15.2% of Aevi Genomic Medicine shares are held by insiders. Comparatively, 1.6% of Affymax shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Aevi Genomic Medicine beats Affymax on 5 of the 9 factors compared between the two stocks.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Affymax Company Profile
Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.